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We identiﬁed a 495 Kb interstitial deletion of chromosome Xp22.2, centered on the AP1S2 gene, by
means of oligonucleotide array comparative genomic hybridisation (array-CGH) in a child with marked
hypotonia in the ﬁrst months of life, psychomotor retardation, severely delayed walking and speech
development, and unspeciﬁc dysmorphic facial features. The deletion was inherited from the healthy
mother. Point mutations of the AP1S2 gene have been identiﬁed in patients with X-linked mental
retardation (XLMR). The clinical features of our patient are quite similar to those reported in male
patients carrying point mutations, thus suggesting that point mutations and deletions of the AP1S2 gene
lead to a recognisable XLMR phenotype in males.
 2011 Elsevier Masson SAS. All rights reserved.1. Introduction
Mental retardation (MR) affects about 1e3% of the population. It
is more common in males (an excess of about 30%) [1] because of
the high incidence of mutations in genes located on the X chro-
mosome that together explain 10e12% of MR in males [2]. More
than 80 X-linked mental retardation (XLMR) genes have so far been
identiﬁed [3,4]. XLMR has been classiﬁed into syndromic and non-
syndromic forms, depending on whether the MR is associated with
other clinical, radiological or metabolic features or not, but this
subdivision appears unsatisfactory since many genes are involved
in both forms [2,5].
The AP1S2 gene (OMIM ID: 300629), which maps to Xp22.2, has
been proposed as a candidate for XLMR because it has been found
to be mutated in seven unrelated XLMR families [6e8]. It encodes
the s1B subunit of clathrin-associated adaptor protein complex 1
(AP1), which is involved in transporting proteins between the
trans-Golgi network and endosomes and interacts with synaptic
vescicle proteins, thus playing an important role in neurotrans-
mitter release [9].
We describe a child with psychomotor retardation, severely
delayed walking and speech development, marked hypotonia
and unspeciﬁc dysmorphic facial features, who was found toGenetica Molecolare, IRCCS
Cusano Milanino MI, Italy.
ti).
on SAS. All rights reserved.carry a cryptic interstitial 495 Kb deletion at Xp22.2, including
the AP1S2 gene.
2. Clinical report
The patient is the only child of a healthy and unrelated 38-year-
old father and 37-year-old mother, whose family histories are
negative for genetic diseases. The results of prenatal ultrasonog-
raphy were normal. The child was born by spontaneous vaginal
delivery at a gestational age of 39 weeks; at birth, his weight was
3.450 kg (50th percentile), length 51 cm (50th percentile), occipi-
tofrontal circumference (OFC) 34 cm (25th percentile), and APGAR
scores 8 and 10 after respectively 1 and 5 min. No major medical
problems were observed during the neonatal period except for
poor sucking. Psychomotor delay and hypotonia became evident at
the age of 4months. The results of various clinical and instrumental
examinations (echocardiography, ophthalmological screening,
brainmagnetic resonance imaging and computed tomography [CT],
muscle CT, electroencephalography, evoked visual and acoustic
potentials, electroretinography) were normal; electromyography
and muscle biopsy revealed only slight and unspeciﬁc anomalies.
The neurological follow-up conﬁrmed the marked hypotonia and
delayed achievement of the ﬁrst psychomotor milestones (nuchal
stability at 9 months, sitting alone at 12 months). The child showed
also hyperreﬂexia, poor social interactions and stereotypies
(repetitive hand movements).
He was referred to us at the age of 13 months, when his weight
was 9.920 kg (10e25th percentile), height 81 cm (75th percentile)
Fig. 1. Frontal photograph of the patient at the age of 13 months (a) and lateral photograph at the age of 4 years (b) showing a long face, bitemporal narrowing, and a bulbous nasal
tip.
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included a long face, bitemporal narrowing, deeply-set eyes, stra-
bismus, up-slanting palpebral ﬁssures, and a bulbous nasal tip
(Fig. 1a).
The results of methylation test of the 15q11.2 region, study of
subtelomeric rearrangements, and molecular analysis of the UBE3A
gene were normal.Fig. 2. Array-CGH proﬁle. Left) Ideogram of the Xp chromosome with the log2 probe ratio pl
indicating the distal and proximal breakpoint positions and the included genes.He underwent his last follow-up evaluation at the age of 4 years,
when his weight was 13.5 kg (3e10th percentile), height 107.5 cm
(90th percentile) and OFC 48.5 cm (3rd percentile). A clinical
examination did not show any change in his facial phenotype
(Fig. 1b), and he was also affected by hypermetropia and con-
stipation. The neuropsychiatric follow-up conﬁrmed the psycho-
motor delay, with signiﬁcantly delayed walking and speechotted as a function of chromosomal position. Right) Magniﬁcation of the deleted region
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and social interactiveness.
3. Material and methods
Array-CGH of genomic DNA from the proband and his parents
was performed using the Human Genome CGH Microarray kit 44K
(Agilent, Santa Clara, CA) and, restricted to the proband, the Human
Genome CGH Microarray kit 244A (Agilent). These platforms allow
a genome-wide survey with an average resolution of respectively
w130 and w50 Kb. The genomic DNAs were labelled and hybri-
dised in accordance with the manufacturer’s protocol, and the
arrays were analysed using Agilent Scan Control (v A8.4.1), Feature
Extraction software (v 10.7.1.1), and DNA Analytics software (v 4.0).
The unbalanced region revealed by the analysis was analysed in
silico using the March 2006 release of the UCSC Genome Browser
(http://genome.ucsc.edu/) and the Database of Genomic Variants
(http://projects.tcag.ca/variation).
The methylation status of the X chromosome in the patient’s
mother was assessed using the Humara Androgen Receptor gene
methylation assay as previously described [10]. The triplet repeats
were separated by means of capillary electrophoresis and analysed
using an ABI PRISM 3005.
4. Results
Array-CGH using the Human Genome CGH Microarray kit 44K
revealed the presence of an interstitial Xp22.2 deletion (not
shown), which was conﬁrmed and more precisely deﬁned by
means of the higher-resolution 244K platform. The breakpoints of
the w495 Kb deletion are located proximally between 16,263,539
and 16,300,564 bp and distally between 15,763,401 and
15,768,918 bp (Fig. 2). The microdeletion includes only two genes:
AP1S2 and GRPR (Fig. 2).
The deletion was no detectable by array-CGH in the father. The
healthy mother appeared carrier of the same imbalance as the
child, while no skewed X-inactivation could be detected (data not
shown).
5. Discussion
Only point mutations in the AP1S2 gene have so far been re-
ported [6e8]. Altogether, three different nonsense mutations
(c.154C > T, c.106C > T and c.226G > T) and three splice site
mutations (c.180-5_180-1del4, c.288þ5G > A and c.289-1G > C)
have been identiﬁed in seven families [8], including three that have
allowed the detection of a linkage to the AP1S2 region [11e14].
All of the previously described affected males have varying
degrees of intellectual disability (from mild to profound) and their
early lives were characterised by marked hypotonia; furthermore,
most of them experienced delayed walking and speech develop-
ment, language disturbances (from no language to minimal
language), without any signiﬁcant dysmorphic features. The
patients for whom a radiological description is available also
showed calciﬁcations of the basal ganglia (see Borck et al. [8] for
a detailed summary of the clinical features of patients harbouring
AP1S2 mutations). The identiﬁed AP1S2 mutations co-segregating
with the disease in the described families seem to underlie
a speciﬁc and recognisable XLMR syndrome.
The clinical ﬁndings in our patient reﬂect most of those
observed in the carriers of deleterious mutations: psychomotor
retardation, a signiﬁcant delay inwalking and speech development,
marked hypotonia in the ﬁrst months of life that subsequently
slightly improved, and unspeciﬁc dysmorphic facial features. A CT
scan at the age of 4 months excluded the presence of cerebralcalciﬁcations, which is consistent with their reported delayed
appearance in childhood [8].
As previously observed in unaffected female mutation carriers,
the proband’s mother, who is heterozygous for the AP1S2 deletion,
shows random X-inactivation and a normal phenotype, thus indi-
cating that gene haploinsufﬁciency is insufﬁcient to induce the
pathological clinical features.
The GRPR gene (OMIM ID: 305670) close to AP1S2 is also deleted
in the child (Fig. 2). This gene encodes the gastrin-releasing peptide
receptor (GRPR), which regulates a broad spectrum of biological
responses, acts as a growth factor in different types of human
cancer, and has been implicated in the pathogenesis of mammalian
neurological and psychiatric disorders, including the neuro-
developmental disorders associated with autism [15,16].
In his early infancy, our patient showed hand stereotypies and
poor social interactions, which are usually reported in patients with
autistic spectrum disorders (ASD). However, it is hazardous to
consider a correlation with the absence of this gene as the ﬁndings
of a recent study of 149 Italian autistic patients do not indicate that
GRPR plays a major role in ASD [17]. The stereotypies of our patient
may therefore also be associated with the AP1S2 deletion because
two of the described XLMR patients with stereotypies have been
diagnosed as having ASD [8].
In conclusion, ours is the ﬁrst description of a patient with
syndromicMR and an AP1S2 deletion. The absence of AP1S2 leads to
clinical features that overlap those associated with inactivating
point mutations in males, thus conﬁrming the involvement of this
gene in a recognisable XLMR syndrome.References
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